ADC Therapeutics SA — Cash Flow (NYSE:ADCT) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Cash from operating activities -168.73 M-233.38 M-136.79 M-118.69 M-123.83 M-141.17 M -141.17 M Cash from investing activities -2.83 M-6.67 M-2.51 M-3.22 M-867 K395 K 395 K Cash from financing activities 494.97 M267.39 M-593 K73.88 M97.05 M150.94 M 150.94 M Free cash flow -168.73 M-233.38 M-136.79 M-121.9 M-124.7 M-141.44 M -141.44 M

Haberler

ADC Therapeutics, ZYNLONTA’ya odaklanıyor

H.C. Wainwright, ADC Therapeutics hisse hedefini 8 dolara yükseltti

ADC Therapeutics SA 2025 Q4 - Results - Earnings Call Presentation (NYSE:ADCT) 2026-03-11

Micron and BioNTech among market cap stock movers on Tuesday

ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates

Adc Thera kazancı $0,20 ile beklentilere göre daha iyi, kâr ise beklentilere göre yüksek

Adc Thera earnings beat by $0.20, revenue topped estimates

ADC Therapeutics 4Ç’te 22,3 milyon dolar gelir bildirdi

ADC Therapeutics reports Q4 revenue of $22.3 million

ADC Therapeutics %70 getiri sağladı, Gerçeğe Uygun Değer hedefine ulaşıldı

ADC Therapeutics delivers 70% return as Fair Value target hit

ADC Therapeutics TD Cowen’da: Lenfoma tedavisinde stratejik genişleme